Arena Pharmaceuticals Competitors

Amgen (NASDAQ:AMGN) and Arena Pharmaceuticals (NASDAQ:ARNA) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk and institutional ownership.

Analyst Ratings

This is a breakdown of recent recommendations for Amgen and Arena Pharmaceuticals, as reported by MarketBeat.com.

Amgen presently has a consensus target price of $254.08, indicating a potential upside of 10.85%. Arena Pharmaceuticals has a consensus target price of $90.3571, indicating a potential upside of 34.76%. Given Arena Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Arena Pharmaceuticals is more favorable than Amgen.

Volatility & Risk

Amgen has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, Arena Pharmaceuticals has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500.

Profitability

This table compares Amgen and Arena Pharmaceuticals' net margins, return on equity and return on assets.

Insider & Institutional Ownership

71.7% of Amgen shares are held by institutional investors. Comparatively, 79.9% of Arena Pharmaceuticals shares are held by institutional investors. 0.4% of Amgen shares are held by insiders. Comparatively, 3.1% of Arena Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Amgen and Arena Pharmaceuticals' top-line revenue, earnings per share and valuation.

Amgen has higher revenue and earnings than Arena Pharmaceuticals. Arena Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Summary

Amgen beats Arena Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Arena Pharmaceuticals (NASDAQ:ARNA) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk and institutional ownership.

Insider & Institutional Ownership

75.2% of Gilead Sciences shares are held by institutional investors. Comparatively, 79.9% of Arena Pharmaceuticals shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by insiders. Comparatively, 3.1% of Arena Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Gilead Sciences and Arena Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gilead Sciences has higher revenue and earnings than Arena Pharmaceuticals. Arena Pharmaceuticals is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Gilead Sciences has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Arena Pharmaceuticals has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Gilead Sciences and Arena Pharmaceuticals, as reported by MarketBeat.com.

Gilead Sciences presently has a consensus target price of $76.1538, indicating a potential upside of 23.71%. Arena Pharmaceuticals has a consensus target price of $90.3571, indicating a potential upside of 34.76%. Given Arena Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Arena Pharmaceuticals is more favorable than Gilead Sciences.

Profitability

This table compares Gilead Sciences and Arena Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Arena Pharmaceuticals beats Gilead Sciences on 8 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Arena Pharmaceuticals (NASDAQ:ARNA) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, institutional ownership and valuation.

Insider and Institutional Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 79.9% of Arena Pharmaceuticals shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Comparatively, 3.1% of Arena Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Vertex Pharmaceuticals and Arena Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than Arena Pharmaceuticals. Arena Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Vertex Pharmaceuticals has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, Arena Pharmaceuticals has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Vertex Pharmaceuticals and Arena Pharmaceuticals, as reported by MarketBeat.

Vertex Pharmaceuticals presently has a consensus target price of $290.8276, indicating a potential upside of 27.38%. Arena Pharmaceuticals has a consensus target price of $90.3571, indicating a potential upside of 34.76%. Given Arena Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Arena Pharmaceuticals is more favorable than Vertex Pharmaceuticals.

Profitability

This table compares Vertex Pharmaceuticals and Arena Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Vertex Pharmaceuticals beats Arena Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Arena Pharmaceuticals (NASDAQ:ARNA) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, institutional ownership and valuation.

Insider and Institutional Ownership

85.9% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 79.9% of Arena Pharmaceuticals shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by company insiders. Comparatively, 3.1% of Arena Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Regeneron Pharmaceuticals and Arena Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than Arena Pharmaceuticals. Arena Pharmaceuticals is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Regeneron Pharmaceuticals has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Arena Pharmaceuticals has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Regeneron Pharmaceuticals and Arena Pharmaceuticals, as reported by MarketBeat.

Regeneron Pharmaceuticals presently has a consensus target price of $628.52, indicating a potential upside of 27.63%. Arena Pharmaceuticals has a consensus target price of $90.3571, indicating a potential upside of 34.76%. Given Arena Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Arena Pharmaceuticals is more favorable than Regeneron Pharmaceuticals.

Profitability

This table compares Regeneron Pharmaceuticals and Arena Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Regeneron Pharmaceuticals beats Arena Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and Arena Pharmaceuticals (NASDAQ:ARNA) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, institutional ownership and valuation.

Insider and Institutional Ownership

78.9% of Biogen shares are held by institutional investors. Comparatively, 79.9% of Arena Pharmaceuticals shares are held by institutional investors. 0.5% of Biogen shares are held by company insiders. Comparatively, 3.1% of Arena Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Biogen and Arena Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Biogen has higher revenue and earnings than Arena Pharmaceuticals. Biogen is trading at a lower price-to-earnings ratio than Arena Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Biogen has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Comparatively, Arena Pharmaceuticals has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Biogen and Arena Pharmaceuticals, as reported by MarketBeat.

Biogen presently has a consensus target price of $306.1290, indicating a potential upside of 24.51%. Arena Pharmaceuticals has a consensus target price of $90.3571, indicating a potential upside of 34.76%. Given Arena Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Arena Pharmaceuticals is more favorable than Biogen.

Profitability

This table compares Biogen and Arena Pharmaceuticals' net margins, return on equity and return on assets.

Seagen (NASDAQ:SGEN) and Arena Pharmaceuticals (NASDAQ:ARNA) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, institutional ownership and valuation.

Analyst Recommendations

This is a breakdown of recent ratings for Seagen and Arena Pharmaceuticals, as reported by MarketBeat.

Seagen presently has a consensus target price of $176.75, indicating a potential downside of 1.38%. Arena Pharmaceuticals has a consensus target price of $90.3571, indicating a potential upside of 34.76%. Given Arena Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Arena Pharmaceuticals is more favorable than Seagen.

Insider and Institutional Ownership

92.0% of Seagen shares are held by institutional investors. Comparatively, 79.9% of Arena Pharmaceuticals shares are held by institutional investors. 31.1% of Seagen shares are held by company insiders. Comparatively, 3.1% of Arena Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Seagen has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Comparatively, Arena Pharmaceuticals has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.

Profitability

This table compares Seagen and Arena Pharmaceuticals' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Seagen and Arena Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Arena Pharmaceuticals has lower revenue, but higher earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than Arena Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Seagen beats Arena Pharmaceuticals on 9 of the 15 factors compared between the two stocks.